Pure Global
NCT06208709

Carpal Arch Space Augmentation (CASA) Clinical Trial

Biomechanical Treatment of CTS Via Carpal Arch Space Augmentation: A Pilot Clinical Trial
University of Arizona·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Carpal Tunnel Syndrome
Drug/Device/Intervention
carpal arch space augmentation (CASA)
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
University of Arizona
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Feb 01, 2026
Enrollment
76 participants
Primary outcome

Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS)

Summary

This research proposes to evaluate the effectiveness of a novel device designed for the
 treatment of carpal tunnel syndrome. The device applies a small cyclic force to the wrist.
 The cycles include a small time period of force is applied, followed by a brief period of no
 force. The device is intended to be worn during hours of sleep. The efficacy of the treatment
 is evaluated based on patient reported outcomes. Treatment efficacy will also be evaluated
 based on comparisons to patient reported outcomes for a SOC treatment.

ICD-10 classifications
Carpal tunnel syndromeTarsal tunnel syndromeArthrosis of first carpometacarpal joint, unspecifiedArthrosis of first carpometacarpal jointOther specified disorders of synovium and tendon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06208709
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06208709 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Arizona and is currently Not yet recruiting. The study focuses on Carpal Tunnel Syndrome. Target enrollment is 76 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.